Kornimate/medical-research-clean huggingface dataset:
skeletal muscle energy metabolism in women with weight loss and ovarian and/or endometrial cancer with weight loss

Conditions: Weight Loss; Ovarian Carcinoma; Endometrial Carcinoma

Summary: the aim is to study skeletal muscle metabolism alterations métaboliques associated with weight loss in women with ovarian and/or endometrial cancer according to bmi.


Eligibility criteria:
case group selection criteria: inclusion criteria: * women aged 18 years old and more * ovarian and/or endometrial cancer * weight loss related to cancer (weight loss \> 5% weight in one month or 10% in 6 months) * indication to therapeutic surgery * women affiliated to social security scheme * women who can understand french and able to sign informed consent exclusion criteria: * unbalanced diabetes * chronic neuromuscular disorder * any severe uncontrolled medical condition control group selection criteria: inclusion criteria: * women aged 18 years and more * surgery indication for a benign endometrial and/ or ovarian disease * patient affiliated to social security scheme * women who can understand french and able to sign informed consent exclusion criteria: * unbalanced diabetes * chronic neuromuscular disorder * any severe uncontrolled medical condition

Keywords: weight loss ovarian cancer endometrial cancer energy metabolism body mass index obesity muscle energy
assessment of peripheral veins doppler ultrasound for diagnosis of acute right heart failure in suspicion or follow-up of pulmonary hypertension

Conditions: Acute Right Heart Failure; Pulmonary Hypertension; Peripheral Veins Doppler Ultrasound

Summary: occurrence of acute right heart failure (arhf) remains common during pulmonary hypertension (ph). right atrial pressure (rap) invasive measurement is the gold standard to diagnose arhf in order to improve diuretic treatment management. existence of indirect signs of arhf on venous doppler ultrasound waveform has long been described, but correlation with rap has not been properly established yet. it is the aim of our study in order to obtain an additional tool to manage arhf.


Eligibility criteria:
inclusion criteria: * adult patient (age ≥ 18 years old) * patient referred to the cardiology department for a right heart catheterization with measurement of rap, regardless of the indication. * free subject, without guardianship or curatorship or subordination * people affiliated to or beneficiary of a social security schemes * informed consent signed by the patient after clear and fair information about the study. exclusion criteria: * minor patient (age \< 18 years) * refusal to participate in the study * patient with hemodynamic instability, unable to tolerate a delay in treatment caused by the ultrasound examination. * patient requiring diuretic treatment within the next 4 hours * patient with a life expectancy of less than 24 hours. * history of proximal deep venous thrombosis involving the inferior vena cava and/or common iliac veins and/or femoral veins. * history of extrinsic venous compression on the inferior vena cava and/or common iliac veins and/or femoral veins. * persons who do not benefit from a social security scheme or who do not benefit from it through a third party. * persons benefiting from reinforced protection, namely minors, pregnant and nursing women, persons deprived of liberty by a judicial or administrative decision, persons staying in health or social institutions, adults under legal protection and finally patients in emergency situations.
clinical evaluation of adhese universal dc in the indirect restorative therapy

Conditions: Dental Caries; Defective Tooth Restorations

Summary: a post market clinical follow up study (pmcf) with adhese universal dc is planned to ensure the safety and efficacy of the product. it is a study with two arms. inlays and onlays for molars and premolars will be luted with adhese universal dc or adhese universal.

this study aims to assess the long-term safety of adhese universal dc in terms of tooth vitality and failure rate of placed restorations. tooth vitality is an indicator for the health status of the dental pulp. a vitality test is performed to acquire information about the vitality of teeth. a healthy dental pulp offers a positive response to the vitality test. once the dental pulp is injured an irreversible inflammatory reaction starts with a possible necrosis of the dental pulp. pulpa necrosis is followed by a negative response to the vitality test.

Eligibility criteria:
inclusion criteria: * age: 18-65 years * indication for indirect restorations (inlay, onlay) in molar or premolar - replacement of insufficient fillings (e.g. due to caries at margins, filling fracture, fracture of the tooth, poor quality of the surface, leaking margin, etc.) or extensive primary caries * the occlusal area of the restoration must cover at least 1/3 of the occlusal area of the tooth. * participant wishes a restoration within the scope of the study (signed informed consent after detailed explanation and study of the patient information) * 2-operative discomfort of the tooth to be restored should not exceed 3 on the visual analogue scale (vas) (0=no pain, 10=maximum conceivable pain) due to temperature stimulus or bite sensitivity * max. 2 restorations per participant in different quadrants. * vital tooth * healthy periodontium, no active periodontitis * contact with adjacent teeth (at least at one side) and opposing teeth present with at least one contact point. * sufficient language skills exclusion criteria: * sufficient isolation not possible, dry working field cannot be guaranteed * participants with a proven allergy to one of the ingredients of the materials used * participants with proven allergy to local anaesthetics * high caries activity/ poor oral hygiene * participants with severe systemic diseases * pregnancy * nonvital tooth or tooth with irreversible pulpitis * indication for direct pulp capping * symptoms of sars-cov2 infection

Keywords: caries restoration
head-to-head comparison of diagnosis value of pulmonary fibrosis on 68ga-fapi-04 and 18f-fdg pet-ct

Conditions: Pulmonary Fibrosis

Summary: 68ga-fibroblast activating protein inhibitors(fapi) has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as inflammatory bowel disease. and it might be more sensitive than fdg in detecting a certain type of inflammations according to our preliminary research. thus this prospective study is going to investigate whether 68ga-fapi pet/ct may be superior for diagnosis, therapy response assessment and follow-up of pulmonary fibrosis than 18f-fdg pet/ct.

pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease.healthy tissue is replaced by altered extracellular matrix and alveolar architecture is destroyed, which leads to decreased lung compliance, disrupted gas exchange, and ultimately respiratory failure and death.pulmonary fibrosis is diagnosed by identification of a pattern of usual interstitial pneumonia on the basis of radiological or histological criteria in patients without evidence of an alternative cause. activated fibroblasts are crucial for fibrotic processes in pulmonary fibrosis. 68ga-fapi has been developed as a tumortargeting agent as fibroblast activation protein is overexpressed in cancerassociated fibroblasts and inflammation. recently，a study shows that fapi-pet/ct imaging is a promising new imaging modality for pulmonary fibrosis.this head-to-head comparisons aims to evaluate the severity of pulmonary fibrosis and the therapy response of 68ga-fapi-04 compared with 18f-fdg in the same group of pulmonary fibrosis patients.

Eligibility criteria:
inclusion criteria: * suspected or confirmed pulmonary fibrosis patients; * signed written consent. exclusion criteria: * pregnancy; * breastfeeding; * known allergy against fapi * any medical condition that in the opinion of the investigator may significantly interfere with study compliance
study of emotion and cognition abilities of children with pws and proposition of an innovative remediation

Conditions: Prader-Willi Syndrome

Summary: the present project project is divided in two parts. the primary aim of the part 1 of this study is to evaluate emotional control abilities of children with prader-willi syndrome (pws) aged from 9 to 15 years and to study repercussions of this supposed lack of abilities on cognitive capacities and behavioral troubles. the study also evaluate influence of the emotional symptomatology of patients on quality of parents' life and on the care of parents and scholar/institutional caregivers. in the second part of this study, the study evaluate the feasibility and the tolerance to a non-invasive device supposed to reduce emotional symptoms in this disease.

prader-willi syndrome (pws) is a rare genetic disorder involving a variety of clinical, behavioral and cognitive symptoms. 83 to 97% of patients have episodes of temper tantrum, associated with an important emotional lability. these different cognitive and behavioral limitations are barriers to the social integration of patients. the pws also has repercussions on well-being and quality of life of the family. thus, the present project focuses on the characteristics of emotional control related to the anger of children with pws and its behavioral, cognitive and social implications. in addition, at a therapeutic level, our project assumes that transcutaneous electrical nerve stimulation (t-vns), a non-invasive, safe and inexpensive method, could be effective in reducing the severity of behavioral disorders such as temper tantrums while improving cognitive performance and social communication in the pws.

Eligibility criteria:
inclusion criteria: * age from 9 to 15 years old * prader-willi syndrome with identified genotype. * no psychiatric disorder neither pws. * severe global symptomatology attested by a cgi-s score exclusion criteria: * identified psychiatric or behavioral disorders * severe visual or hearing impairment. * sleep apnea syndrome treated with non-invasive ventilation, * epileptic seizures * cardiac disorders.

Keywords: emotion cognition
a study to compare the efficacy and safety of bms-986393 versus standard regimens in adult participants with relapsed or refractory and lenalidomide-refractory multiple myeloma (quintessential-2)

Conditions: Relapsed or Refractory Multiple Myeloma (RRMM)

Summary: the purpose of this study is to compare the efficacy and safety of bms-986393 versus standard regimens in adult participants with relapsed or refractory and lanalidomide-refractory multiple myeloma.


Eligibility criteria:
inclusion criteria * participants must have relapsed or refractory multiple myeloma (rrmm). * participants must have received at least 1 but no greater than 3 prior multiple myeloma (mm) regimens which may include a proteasome inhibitor (pi), an immunomodulatory drug (imid), and an anti-cd38 monoclonal antibody, and be refractory to lenalidomide (len) (progression on or within 60 days of completing len therapy). * participants must have a documented diagnosis of mm as per international myeloma working group criteria. * participants must have measurable disease during screening. * participants must have adequate organ function. * participants must have an eastern cooperative oncology group performance status 0 or 1. exclusion criteria * participants must not have known active or history of central nervous system (cns) involvement of multiple myeloma (mm). * participants must not have solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease. * participants must not need urgent treatment due to rapidly progressing mm. * other protocol-defined inclusion/exclusion criteria apply.

Keywords: relapsed or refractory multiple myeloma multiple myeloma bms-986393 chimeric antigen receptor t-cell (car t-cell) car t-cell therapy
research of serum procalcitonin, esr, crp and leukocyte levels in fertile missed abortion cases

Conditions: Abortion, Missed

Summary: aim: the serum procalcitonin, erythrocyte sedimentation rate, c-reactive protein and leukocyte values will be compared between fertile missed abortion diagnosed pregnants and fertile normal pregnants to determine the presence of subclinical infection in the etiology of missed abortion

the study group will consist of 30 fertile, under 35 years old women having for the first time missed abortus diagnosis in the obstetrics department of obstetrics and gynecology of medicine faculty of karadeniz technical university, medical faculty of medicine. as control group, 30 cases with the same trimester, fertile, and under 35 years old who had referred to obstetrics clinic, who had no systemic disease, will be included in the study. blood samples will be collected at the time of diagnosis of the patients with missed abortion and in normal pregnancy in the week of 20th gestational week and will send to biochemistry laboratory to examine procalcitonin, erythrocyte sedimentation rate, c-reactive protein and leukocyte values in their sera. the age, weight, gestational week, gravida (number), parity (number), abortus (number), body mass index, systemic diseases, blood group, smoking information, binary test results, and results of genetic analysis will be collected in both groups. the pathology results of the missed abortion group will also be collected. the results will statistically be compared in the spss 13.0 program in both groups.

Eligibility criteria:
inclusion criteria: * fertile, less than 20 weeks of geese who have missed abortus for the first time without systemic disease exclusion criteria: * failure to meet the missed abortus diagnostic criteria (for the group of fertile missed abortus) * smoking * rejection to participate in the study.

Keywords: missed abortion procalcitonin erythrocyte sedimentation rate (esr) c-reactive protein (crp) leukocyte (wbc)
a prospective observational study of clinical outcomes for the nanostring® technologies prosigna gene signature assay

Conditions: Breast Cancer

Summary: the primary objective of this study is to assess the extent to which the prosigna™ breast cancer prognostic gene signature assay affects the medical oncologist's treatment recommendations regarding adjuvant chemotherapy and actual treatments received for patients with early-stage breast cancer.

changes in treatment recommendations will include (1) hormonal therapy alone, (2) hormonal therapy plus chemotherapy, and (3) changes in types of chemotherapy if chemotherapy was recommended before and after the prosigna test.

Eligibility criteria:
inclusion criteria: * resected node-negative, estrogen-receptor-positive, her2-negative early- stage invasive breast cancer (t1-t2, n0, pn0 (i+), pn0 (mol+), m0) 1. estrogen receptor status will be evaluated by immunohistochemistry (ihc)and more than 1% of stained tumor cells will be considered positive. 2. her2 status will be evaluated by (ihc; 0 or 1+, or 2+ will be considered negative) and by in-situ fluorescence hybridization. * postmenopausal females, which is defined as: 1. natural amenorrhea \> 12 months, regardless of age 2. bilateral oophorectomy, regardless of age (the oophorectomy must have been carried out at least 4 weeks before entering the study) 3. radiological castration with amenorrhea \> 3 months, regardless of age 4. hysterectomy and postmenopausal blood levels * able to give consent * eligible for treatment of breast cancer with adjuvant chemotherapy * ecog performance status of 0 or 1 exclusion criteria: * tumor size t3-t4 * non-invasive breast cancer (e.g., paget's disease, dcis) * tumors with nodes that are not n0, pn0 (i+), or pn0 (mol+) * tumors that are estrogen-receptor negative or her2 positive * have metastatic disease * unable to give informed consent * unable to complete patient reported outcome surveys * have contraindications for adjuvant chemotherapy * age, performance status, significant comorbidities * ecog performance status \> 1

Keywords: breast cancer prosigna ffpe node negative estrogen receptor positive her2 negative
patient reported outcome and experience measures for bronchoscopic procedures

Conditions: Bronchial Diseases

Summary: 'patient-reported outcomes' (proms) and 'patient-reported experiences' (prems) are increasingly important parameters in evaluating and adjusting clinical procedures and strategies in healthcare. validated disease-specific proms related to bronchoscopic procedures are not available and examples in the medical literature are very scarce.

the potential usefulness of prom/prems is multiple: 1. quality improvement within the current clinical care structure 2. monitoring the health status of the population 3. contribution to decision-making regarding financing of care 4. increase employee and patient involvement in clinical care pathways 5. rationalize the deployment of medical personnel and resources 6. integration of data in electronic patient files and registers

Eligibility criteria:
inclusion criteria: * age above 18 years * patient referred for diagnostic flexible bronchoscopy * procedure performed in outpatient setting exclusion criteria: * patient unable to adequately respond to the contents of the patient questionnaire. * procedure performed in hospitalised setting * patient with active pregnancy

Keywords: bronchoscopy endoscopy patient reported outcome measures
mri for the diagnosis of placenta accreta spectrum

Conditions: Placenta Accreta

Summary: placenta accreta spectrum (pas) is a disease associated with abnormal placental adhesion and invasion. in recent years, the incidence of pas has increased significantly, which can cause massive postpartum hemorrhage, hysterectomy,and even maternal mortality. the research team of peking university third hospital developed the ultrasound rating scale in china at first to conduct preliminary assessment of the pas risk which can identify the severity of cases. in a basis of ultrasound, plan to explore the mri for the the investigators diagnosis of pas according to some specific pas features, like the the uneven signal intensity , the myometrial discontinuity, and black band on t2 image, and finally established a mri scoring system of pas. mri score system of pas can reduce the subjective difference of the clinician's visual reading, and assist the clinician to assess the risk of sever pas further, and conduct perioperative preparation to reduce the risk of maternal morbidity and mortality to achieve a better clinical outcome.

placenta accreta spectrum (pas) is a disease associated with abnormal placental adhesion and invasion. in recent years, the incidence of pas has increased significantly, and the main risk is high hysterectomy rate,massive postpartum hemorrhage, and even maternal mortality in women at childbearing age. the research team of peking university third hospital developed the ultrasound rating scale in china at first to conduct preliminary assessment of the pas risk which can identify the severity of cases and guide the junior hospitals to transfer. peking university third hospital is in the leading position in the preoperative diagnosis of pas currently. magnetic resonance imaging (mri) has become a common method for preoperative evaluation for sever cases. mri can provide a map of the placenta and pas features, like the uterus enlarged significantly, the uneven signal intensity , the myometrial discontinuity, and black band on t2 image. it has a high diagnostic value. at present, only lim and ueno reported mri scoring system for pas. due to the small sample size and the limitation of the research methods, a widely applicable rating scale has not been established. mri score system of pas can reduce the subjective difference of the clinician's visual reading, and assist the clinician to assess the risk of sever pas further, and conduct perioperative preparation to reduce the risk of maternal morbidity and mortality and achieve a better clinical outcome.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed as scarred uterus(with a history of cesarean section) 2. "ultrasound score" of pas≥ 6 points who undergo mri 3. terminate pregnancy or childbirth in peking university third hospital. - exclusion criteria: 1. patients who didn't undergo mri 2. patients who didn't deliver the baby in puth -

Keywords: placenta accreta spectrum mri score scale diagnosis
biological collection of brain tumors

Conditions: Brain Tumor

Summary: the objective of this study is to build a collection of biological samples from patients with brain tumors.


Eligibility criteria:
inclusion criteria: * patient whose diagnosis of brain tumor has been confirmed. * adult patients, from 18 years old and without upper age limit * patient affiliated to a social security scheme or equivalent. * patient able to consent, having dated and signed an informed consent exclusion criteria: * pregnant or breastfeeding women * patient under guardianship or curators. * persons deprived of their liberty by a judicial or administrative decision

Keywords: brain tumor
a depot formulation of sunitinib malate (gb-102) compared to aflibercept in subjects with wet amd

Conditions: Neovascular Age-Related Macular Degeneration

Summary: phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of repeated ivt injections of 3 dose levels of gb-102 compared with aflibercept.

phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of the effect of gb-102, as measured by time to first rescue treatment across multiple dose levels of gb-102 administered every 6 months as compared to intravitreal (ivt) aflibercept administered every 2 months in subjects with neovascular (wet) age-related macular degeneration who have received prior induction with anti-vascular endothelial growth factor (vegf) extension study: to monitor the safety and duration of effect of ivt gb-102 administered every 6 months compared to ivt aflibercept administered every 2 months in subjects in altissimo (core study) who complete all study visits through month 12 (day 360) and who do not require/receive rescue treatment at the month 12 (day 360) final study visit

Eligibility criteria:
inclusion criteria: * males or females ≥ 50 years of age * presence of a choroidal neovascularization (cnv) lesion secondary to amd treated with at least 3 prior intravitreal (ivt) injections of an anti-vascular endothelial growth factor (vegf) agent (aflibercept, bevacizumab, or ranibizumab). * demonstrated response to prior anti-vegf treatment since diagnosis * best-corrected visual acuity (bcva) of 35 letters or better exclusion criteria: * history, within 6 months prior to screening, of any of the following: myocardial infarction, any cardiac event requiring hospitalization, treatment for acute congestive heart failure, transient ischemic attack, or stroke * uncontrolled hypertension, diabetes mellitus or intraocular pressure (iop) * chronic renal disease * abnormal liver function * women who are pregnant or lactating

Keywords: age-related macular degeneration (amd) choroidal neovascularization